Ionis Pharmaceuticals, Inc.
IONS
$33.53
$1.273.94%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 131.61M | 226.58M | 133.81M | 225.25M | 119.50M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 131.61M | 226.58M | 133.81M | 225.25M | 119.50M |
| Cost of Revenue | 194.92M | 249.32M | 220.83M | 226.23M | 209.27M |
| Gross Profit | -63.31M | -22.74M | -87.02M | -978.00K | -89.77M |
| SG&A Expenses | 83.55M | 88.08M | 61.64M | 65.11M | 59.74M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 278.47M | 337.40M | 282.47M | 291.34M | 269.01M |
| Operating Income | -146.86M | -110.82M | -148.66M | -66.09M | -149.51M |
| Income Before Tax | -146.82M | -107.04M | -144.10M | -66.20M | -142.73M |
| Income Tax Expenses | 116.00K | -2.69M | -3.62M | 64.00K | 75.00K |
| Earnings from Continuing Operations | -146.94M | -104.35M | -140.48M | -66.27M | -142.80M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -146.94M | -104.35M | -140.48M | -66.27M | -142.80M |
| EBIT | -146.86M | -110.82M | -148.66M | -66.09M | -149.51M |
| EBITDA | -144.05M | -108.12M | -145.68M | -63.00M | -146.33M |
| EPS Basic | -0.93 | -0.66 | -0.95 | -0.45 | -0.98 |
| Normalized Basic EPS | -0.57 | -0.41 | -0.61 | -0.27 | -0.62 |
| EPS Diluted | -0.93 | -0.66 | -0.95 | -0.45 | -0.98 |
| Normalized Diluted EPS | -0.57 | -0.41 | -0.61 | -0.27 | -0.62 |
| Average Basic Shares Outstanding | 158.74M | 158.00M | 148.59M | 145.96M | 145.54M |
| Average Diluted Shares Outstanding | 158.74M | 158.00M | 148.59M | 145.96M | 145.54M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |